Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MYOC | Q99972 | 1/20 | 0.58 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27765 | 0.89 | MAPK1 (1.00) | MAPK1MAPTMAOBSRD5A2MEN1 | |
| Ammonia Solution, Strong SCHEMBL17180526 | 0.87 | MAPK1 (0.96) | MAPK1MAPTMAOBSRD5A2MEN1 | |
| Bromide SCHEMBL8031021 | 0.87 | MAPK1 (0.96) | MAPK1MAPTMAOBSRD5A2MEN1 | |
| Methyl Alcohol SCHEMBL28098714 | 0.87 | MAPK1 (0.96) | MAPK1MAPTMAOBSRD5A2MEN1 | |
| SCHEMBL10943864 | 0.85 | SRD5A2 (0.87) | MAPK1MAPTRAB9ASRD5A2MEN1 | |
| Acetic Acid SCHEMBL28719519 | 0.85 | MAPK1 (0.92) | MAPK1MAPTMAOBSRD5A2MEN1 | |
| SCHEMBL6986709 | 0.85 | KMT2A (0.72) | MAPK1MAPTRAB9AHPGDMAOB | |
| SCHEMBL4457648 | 0.84 | MAOB (0.64) | MAPK1MAPTRAB9AHPGDMAOB | |
| SCHEMBL10628045 | 0.84 | SRD5A2 (0.59) | MAPK1MAPTRAB9AMAOBSRD5A2 | |
| SCHEMBL28561063 | 0.84 | SRD5A2 (0.90) | MAPK1MAPTRAB9ASRD5A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143339-A | Preparation method of polyimide film material containing furan pyridine structure | 沈阳化工大学 | 2023-12-01 | — | — | CN | claimed |
| CN-103788008-B | The preparation method of the diamine compound containing thiazole ring | 中国科学院兰州化学物理研究所 | 2017-07-14 | — | — | CN | claimed |
| CN-117143339-A | Preparation method of polyimide film material containing furan pyridine structure | 沈阳化工大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-105714409-B | A kind of molecule based on electrospinning assembles the preparation method of poly- pyrrole throat/polyimides composite nano fiber | 江西师范大学 | 2019-01-29 | — | — | CN | disclosed |
| EP-2755722-B1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC LTD (IN) | 2017-05-24 | — | — | EP | disclosed |
| CN-105714409-A | Electrospinning-based preparation method of molecule-assembling polypyrrolone/polyimide composite nano fibers | 江西师范大学 | 2016-06-29 | — | — | CN | disclosed |
| US-9018249-B2 | SGLT inhibitors | PANACEA BIOTEC LIMITED (IN) | 2015-04-28 | — | — | US | disclosed |
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2014-12-25 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2755722-A2 | NOVEL SGLT INHIBITORS | Panacea Biotec Ltd. (IN) | 2014-07-23 | — | — | EP | disclosed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK1 447/4885MAPT 2180/4885RAB9A 1936/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | MAPK1 356/4885MAPT 2754/4885RAB9A 1400/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK1 564/4885MAPT 2299/4885RAB9A 2093/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK1 564/4885MAPT 2299/4885RAB9A 2093/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK1 286/4885MAPT 2474/4885RAB9A 2639/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | MAPK1 391/4885MAPT 2928/4885RAB9A 1099/4885 |
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | SLC5A1, SLC5A2, SLC2A1 | MAPK1 539/4885MAPT 65/4885RAB9A 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.